8-K: FDA Issues CRL for Scholar Rock's Apitegromab BLA

Scholar Rock announced the FDA issued a Complete Response Letter for its apitegromab BLA for SMA, citing issues at a third-party manufacturing facility, not related to the drug's efficacy or safety.

Summary

• The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for apitegromab for the treatment of spinal muscular atrophy (SMA).
• The CRL is solely related to observations identified during a routine general site inspection of Catalent Indiana LLC, a third-party fill-finish facility, which was acquired by Novo Nordisk A/S in December 2024.
• The observations cited in the CRL are not specific to apitegromab and were previously discussed during Scholar Rock's second quarter 2025 earnings announcement.
• The FDA did not cite any other approvability concerns, including apitegromab's efficacy and safety data or the third-party drug substance manufacturer.
• Scholar Rock intends to resubmit the apitegromab BLA upon successful remediation of the FDA observations by Catalent Indiana LLC.
• The company believes the FDA will be able to act expeditiously on the application once the manufacturing issues are resolved.
• Outside the U.S., the apitegromab marketing authorization application (MAA) is under review by the European Medicines Agency (EMA), with a decision anticipated near mid-2026.
• European launch is anticipated in the second half of 2026, with Germany expected to be the first European market with patient access.

Sentiment

Score: 4

Explanation: The issuance of a Complete Response Letter (CRL) is a significant negative event, delaying U.S. market entry for a key product. However, the underlying reason for the CRL is external (manufacturing facility issues) and not related to the drug's efficacy or safety, which is a mitigating factor. The company's clear intent to resubmit and the ongoing European review provide some optimism, but the immediate impact is a setback.

Positives

• The Complete Response Letter (CRL) is solely related to observations at a third-party manufacturing facility and not to apitegromab's efficacy or safety data.
• The CRL did not cite any concerns regarding the third-party drug substance manufacturer.
• Apitegromab has received multiple expedited designations, including Orphan Drug, Rare Pediatric Disease, Priority Review, and Fast Track designations from the FDA, and Priority Medicines (PRIME) and Orphan Medicinal Product designations from the EMA.
• The European Medicines Agency (EMA) is continuing its review of the apitegromab MAA, with a decision anticipated near mid-2026 and European launch in the second half of 2026.

Negatives

• The FDA issued a Complete Response Letter (CRL) for the apitegromab Biologics License Application (BLA), delaying its potential approval in the U.S.
• The availability of a muscle-targeted treatment approach for patients with SMA in the U.S. has been delayed due to manufacturing observations at a third-party facility.

Risks

• Whether the FDA observations related to Catalent Indiana LLC are resolvable in a timely manner or at all.
• Whether Scholar Rock will be able to resubmit its BLA in a timely manner.
• Whether the updated BLA will be sufficient to support regulatory approval.
• Information provided or decisions made by regulatory authorities.
• Competition from third parties that are developing products for similar uses.
• Scholar Rock's ability to obtain, maintain, and protect its intellectual property.
• Scholar Rock's dependence on third parties for development and manufacture of product candidates, including to supply any clinical trials.

Future Outlook

Scholar Rock intends to resubmit the apitegromab BLA to the FDA upon successful remediation of the manufacturing observations at Catalent Indiana LLC. The company believes the FDA will be able to act expeditiously on the application once these issues are resolved. In Europe, a decision on the marketing authorization application is anticipated near mid-2026, with a European launch expected in the second half of 2026, starting with Germany.

Management Comments

• "We are continuing to work closely with Catalent Indiana on the FDA’s manufacturing observations so that we can resubmit the apitegromab BLA as soon as possible." David L. Hallal, Chairman and Chief Executive Officer of Scholar Rock.
• "We remain focused on working hand-in-hand with the FDA to pursue approval of the first and only muscle-targeted treatment for people living with SMA." David L. Hallal, Chairman and Chief Executive Officer of Scholar Rock.
• "While we are disappointed that the availability of a muscle-targeted treatment approach for patients with SMA has been delayed, we remain enthusiastic about the transformative potential of apitegromab." Kenneth Hobby, President of Cure SMA.
• "Muscle strength and motor function are significant unmet needs for many in the SMA community and are fundamental to independence." Kenneth Hobby, President of Cure SMA.

Industry Context

The filing highlights the ongoing need for muscle-targeted treatments in Spinal Muscular Atrophy (SMA), as existing SMN-targeted therapies primarily prevent motor neuron loss but do not directly address muscle function. Apitegromab aims to fill this unmet need by inhibiting myostatin activation to improve muscle mass and strength. The delay due to manufacturing issues at a third-party facility underscores the stringent regulatory environment for biopharmaceutical products, where manufacturing quality is a critical component of the approval process, even for promising therapies addressing high unmet medical needs.

Comparison to Industry Standards

• Apitegromab is noted as the first muscle-targeted treatment candidate in SMA to demonstrate clinical success in a pivotal Phase 3 clinical trial, differentiating it from existing SMN-targeted treatments.
• Approximately 35,000 SMA patients globally have been treated with an SMN-targeted treatment, indicating a significant patient population that could benefit from additional, complementary therapies like apitegromab that address muscle function.
• The delay caused by manufacturing observations at a contract manufacturing organization (Catalent Indiana LLC) is a common industry challenge, reflecting the high regulatory standards for pharmaceutical production and quality control across the entire supply chain.

Stakeholder Impact

• Shareholders: Likely negative impact on share price due to delayed U.S. market entry and increased uncertainty regarding the approval timeline.
• SMA Patients: Delayed access to a potentially transformative muscle-targeted treatment in the U.S., which could address unmet needs not fully covered by existing therapies.
• Employees: Potential impact on morale and operational focus due to the regulatory setback, though the company's commitment to resubmission provides a clear path forward.
• Catalent Indiana LLC: Increased scrutiny and pressure to resolve FDA observations, impacting their operational focus and potentially their reputation.
• Novo Nordisk A/S: As the acquirer of Catalent Indiana LLC, there could be an indirect impact on their reputation and operational efficiency related to the manufacturing facility issues.

Next Steps

• Catalent Indiana LLC is to continue working rapidly to take corrective action and remediate the FDA observations at its fill-finish facility.
• Scholar Rock will resubmit the apitegromab BLA to the FDA upon successful remediation of the manufacturing observations by Catalent Indiana LLC.
• The FDA is expected to act expeditiously on the resubmitted application once the manufacturing issues have been resolved.
• The European Medicines Agency (EMA) will continue its review of the apitegromab MAA, with a decision anticipated near mid-2026.
• Anticipated European launch of apitegromab in the second half of 2026, with Germany expected to be the first market.

Key Dates

Recommendation

The FDA's Complete Response Letter (CRL) is a significant setback, delaying the U.S. market entry for apitegromab. This introduces near-term uncertainty and potential downward pressure on the stock. However, the critical detail is that the CRL is solely due to manufacturing observations at a third-party facility and not related to the drug's efficacy, safety, or the company's clinical data. This suggests the core value proposition of apitegromab remains intact. The company's clear plan to resubmit the BLA upon resolution of the manufacturing issues, coupled with the ongoing European review, provides a path forward. A 'hold' recommendation is appropriate as investors should await further updates on the manufacturing remediation timeline and the subsequent BLA resubmission, as these events will be key determinants of future stock performance.

Keywords

SMA, apitegromab, FDA, Complete Response Letter, Biologics License Application, Catalent Indiana, Spinal Muscular Atrophy, myostatin, biopharmaceutical, rare disease, neuromuscular